ArciTect™ Annealing Buffer (5X)

For guide RNA generation in CRISPR-Cas9 genome editing

Catalog # 76020 1 mL

STEMCELL™ TECHNOLOGIES
Scientists Helping Scientists™ | WWW.STEMCELL.COM
TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713
INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM
FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

ArciTect™ Annealing Buffer (5X) is required to anneal ArciTect™ tracrRNA (Catalog #76016/76017/76018) and ArciTect™ crRNA (Catalog #76010/76011/76012) to form a guide RNA (gRNA) duplex. This product is a refill component for ArciTect™ tracrRNA Kit.

Properties

Storage: Store at -20°C. Alternatively, store at 2 - 8°C for up to 6 months.
Shelf Life: Stable for 24 months from date of manufacture (MFG) on label.
Contains: HEPES and potassium acetate, pH 7.5

Directions for Use

For complete instructions on CRISPR-Cas9 genome editing, refer to the Technical Bulletin: Human Pluripotent Stem Cell Genome Editing Using the ArciTect™ CRISPR-Cas9 System (Document #27084), available at www.stemcell.com or contact us to request a copy.

Related Products

For related products, including other genome editing tools, specialized cell culture and storage media, supplements, antibodies, cytokines, and small molecules, visit www.stemcell.com or contact us at techsupport@stemcell.com.

References

Gundry MC et al. (2016) Highly efficient genome editing of murine and human hematopoietic progenitor cells by CRISPR/Cas9. Cell Rep 17(5): 1453–61.

Hultquist JF et al. (2016) A Cas9 ribonucleoprotein platform for functional genetic studies of HIV-host interactions in primary human T cells. Cell Rep 17(5): 1438–52.

Kim S et al. (2014) Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 24(6): 1012–9.

Liang X et al. (2015) Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol 208: 44–53.

Ran FA et al. (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154(6): 1380–9.

Rupp LJ et al. (2017) CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep 7(1): 737.